pf-07275315
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 9, 2022 (NCT05411588)
Timeline
Indications
Mechanism of action
IL13RA2 inhibitor
- Interleukin-4INHIBITOR
IL4 inhibitor
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06977581 | Phase 2 | May 20, 2025 | Pfizer |
| NCT06675188 | Phase 1 | Jan 14, 2025 | Pfizer |
| NCT05995964 | Phase 2 | Aug 22, 2023 | Pfizer |
| NCT05411588 | Phase 1 | Jun 9, 2022 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 2 | 2022 |
1 organizations
Page 1 / 1